-
公开(公告)号：US20240360201A1
公开(公告)日：2024-10-31
申请号：US18643334
申请日：2024-04-23
Inventor： Yuan Guo , Baihong Liu , Yi Yang , Yuelei Shen
CPC classification number: C07K16/00 , C07K14/52 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/622 , C07K2319/00
Abstract: This disclosure relates to modified immunoglobulins.
-
公开(公告)号：US20240360184A1
公开(公告)日：2024-10-31
申请号：US18768336
申请日：2024-07-10
Applicant: Molecular Templates, Inc.
Inventor： Eric POMA , Erin WILLERT , Garrett Lee ROBINSON , Sangeetha RAJAGOPALAN , Brigitte BRIESCHKE
IPC: C07K14/25 , A61K39/00 , C07K14/245 , C07K16/00 , C07K16/08 , C07K16/10 , C07K16/28 , C07K16/32 , C12N9/10 , C12N9/24 , C12N15/62
CPC classification number: C07K14/25 , C07K14/245 , C07K16/00 , C07K16/085 , C07K16/088 , C07K16/089 , C07K16/1063 , C07K16/286 , C07K16/2863 , C07K16/2866 , C07K16/2887 , C07K16/32 , C12N9/1077 , C12N9/2497 , C12N15/62 , C12Y204/02036 , C12Y302/02022 , A61K2039/6037 , C07K2319/04 , C07K2319/33 , C07K2319/40 , C07K2319/55 , Y02A50/30
Abstract: The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.
-
公开(公告)号：US20240336671A1
公开(公告)日：2024-10-10
申请号：US18743257
申请日：2024-06-14
Applicant: FUJIFILM Corporation
Inventor： Hiroshi SAKUYAMA , Naoto TAKAHASHI
Abstract: An object of the present invention is to provide a method for producing a product by cell culture, which makes it possible to suppress the clogging of an exhaust filter due to bubbles generated on an upper surface of a culture solution, and a cell culture device that makes it possible to suppress the clogging of an exhaust filter due to bubbles generated on an upper surface of a culture solution. According to the present invention, there is provided a method for producing a product, which includes culturing a cell using a cell culture device to produce a product from the cell, where the cell culture device includes a culture container accommodating a cell suspension containing cells and at least one or more bubble trap containers capable of accumulating bubbles, the one or more bubble trap containers being connected to an outside of the culture container.
-
公开(公告)号：US20240335534A1
公开(公告)日：2024-10-10
申请号：US18752089
申请日：2024-06-24
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Mayank PATEL , Stacy WASINGER , Danya SPRITZER , Xiaolin TANG
IPC: A61K39/395 , A61K9/00 , A61K38/46 , A61K47/26 , C07K16/00
CPC classification number: A61K39/39591 , A61K38/465 , A61K47/26 , C07K16/00 , A61K9/0019
Abstract: Biopharmaceutical compositions and drug products disclosed herein exhibit reduced amounts of subvisible particle formation. Compositions and drug products disclosed herein comprise a protein and a surfactant or stabilizer including high percentage amounts of a long-chain fatty acid ester. Also disclosed herein are methods of preparing and storing such compositions and drug products.
-
公开(公告)号：US20240327890A1
公开(公告)日：2024-10-03
申请号：US18741057
申请日：2024-06-12
Applicant: Hoffmann-La Roche Inc.
Inventor： Oliver POPP , Nicola BEAUCAMP , Georg DRABNER , Stephanie ESSLINGER
CPC classification number: C12P21/005 , C07K16/00 , C12N1/38 , C07K2317/41
Abstract: The present invention relates to methods for selecting between conditions which enhance cell growth or biomass generation and conditions which affect the N-glycosylation maturity of expressed glycoprotein produced by eukaryotic cells under fermentation culture conditions. Thus, in the methods of the present invention, the glycoprotein producing cells are cultured in a medium which is tailored to a desired end result. The invention also embraces the medium and the use thereof.
-
Patent Agency Ranking
公开(公告)号：US12098406B2
公开(公告)日：2024-09-24
申请号：US17852951
申请日：2022-06-29
Applicant: Sutro Biopharma, Inc.
Inventor： Martin Chandler , Kirk Hayenga , Henry Heinsohn
IPC: C12P21/00 , C07K14/535 , C07K16/00 , C12P1/04 , C12P21/02
CPC classification number: C12P21/00 , C07K14/535 , C07K16/00 , C12P1/04 , C12P21/02
Abstract: This invention provides for an improved method of stabilizing freeze dried bacterial extracts with a carbohydrate lyoprotectant such that the extracts can be for use in cell free protein synthesis. Also provided herein are formulations for stable, freeze dried bacterial extracts that when stored at room temperature retain at least about 70% protein synthesis activity compared to undried frozen bacterial extracts.
-
公开(公告)号：US12091444B2
公开(公告)日：2024-09-17
申请号：US16805425
申请日：2020-02-28
Applicant: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Inventor： Vikram Arora , Ralph Christian Crumrine , Kristine Bergstrand , Hongbin Li , Todd W. Willis
CPC classification number: C07K16/00 , A61K9/0021 , A61K39/00 , A61M37/00 , A61K2039/505 , A61K2039/54
Abstract: A method for administration of an IgG preparation by an intradermal (ID) route to a subject includes loading with a volume of the IgG preparation an ID delivery device including needles, applying the device to a skin delivery site, using the device to allow dermal penetration of the needles, delivering the volume of the IgG preparation at the skin delivery site, and removing the injection delivery device. The method can be used in the treatment of a disease, such as an immunodeficiency.
-
公开(公告)号：US20240301370A1
公开(公告)日：2024-09-12
申请号：US18523811
申请日：2023-11-29
Applicant: VEGENICS PTY LIMITED
Inventor： Michael Gerometta , Timothy Adams
CPC classification number: C12N9/12 , A61K38/45 , A61K39/395 , A61K45/06 , A61K47/64 , C07K14/71 , C07K16/00 , A61K38/00 , C07K2319/00 , C07K2319/03 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N2710/10043 , C12Y207/10001
Abstract: The present invention is directed to ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis.
-
公开(公告)号：US20240293332A1
公开(公告)日：2024-09-05
申请号：US18659740
申请日：2024-05-09
Applicant: Elektrofi, Inc.
Inventor： Paul Brown , Lyndon Fitzgerald Charles, JR. , Chase Spenser Coffman , Daniel Benjamin Dadon , James W. Ivey , Lisa Liu , Chaitanya Sudrik
Abstract: The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.
-
公开(公告)号：US12077796B2
公开(公告)日：2024-09-03
申请号：US16615419
申请日：2018-05-29
Applicant: UCB BIOPHARMA SRL
Inventor： Bassem Ben Yahia , Laetitia Malphettes , Nadine Kochanowski , Gill Renner , Sandrine Durran , Andrew Jeffrey Yates
CPC classification number: C12P21/02 , C07K1/16 , C07K16/00 , C12N5/0018 , C07K2317/14 , C07K2317/565 , C12N2500/32 , C12N2510/02 , C12N2511/00 , C12N2523/00
Abstract: The present invention relates to the use of limited amounts of cysteine and tryptophan in the cell culture medium during production of recombinant proteins, and in particular antibodies. Proteins and antibodies produced under such controlled conditions exhibit reduced heterogeneity, in particular reduced charge variants heterogeneity.
-
-
-
-
-
-
-
-
-
Search Results
7250
records
(took 0.034 seconds)
